Changes in Hong Kong stocks | Innovative drug concept stocks are rising across the board, WCLC clinical data is heavy, catalytic agencies indicate that allocation value is highlighted after the pullback

Zhitong Finance App learned that innovative drug concept stocks rose across the board. As of press release, Nuochengjianhua (09969) rose 10.78% to HK$15; Kang Fang Biotech (09926) rose 5.37% to HK$95.15; Sansheng Pharmaceutical (01530) rose 4.60% to HK$16.15; China Biopharmaceuticals (01177) rose 3.62% to HK$5.44; and Cinda Biotech (01801) rose 2.67% to HK$96.05.

According to the news, on September 12-15, the 2026 World Lung Cancer Conference (WCLC) was held, and clinical data on a number of innovative Chinese drugs were unveiled. Kangfang Biotech's single drug OS data and B7H3ADC were the focus. At the same time, the 2026 national health insurance catalogue negotiations came to an end, the commercial insurance innovative drug catalogue progressed simultaneously, payment-side reform expectations heated up, and the industrial logic of “commercialization overseas plus payment improvement” continued to strengthen.

Zhongtai Securities pointed out that WCLC's concentrated disclosure of clinical advances in the field of lung cancer has further verified the clinical value and global competitiveness of innovative drugs in China, and may be able to actively seize deployment opportunities for innovative drugs after the pullback. Agencies generally believe that new orders from some companies entered the revenue confirmation period in the third quarter, and fundamentals are expected to continue to improve. The current valuation of the pharmaceutical sector is 27 times PE, which is lower than the historical average, and the allocation value is prominent after the pullback.